168 related articles for article (PubMed ID: 6773656)
1. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
[TBL] [Abstract][Full Text] [Related]
2. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
3. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
4. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W
Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202
[TBL] [Abstract][Full Text] [Related]
5. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
6. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Chang YC; Falkson G; Tormey DC; Crowley J
Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
[TBL] [Abstract][Full Text] [Related]
7. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
10. [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
Israël L; Lepage E; Breau JL; Aguilera J
Bull Cancer; 1982; 69(5):426-33. PubMed ID: 6891902
[TBL] [Abstract][Full Text] [Related]
11. [Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Grigorova TM; Vartanian LG; Marenich AF
Vopr Onkol; 1980; 26(2):81-5. PubMed ID: 6767311
[TBL] [Abstract][Full Text] [Related]
12. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
[TBL] [Abstract][Full Text] [Related]
13. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
[No Abstract] [Full Text] [Related]
14. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S
Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200
[TBL] [Abstract][Full Text] [Related]
15. [Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
Pouillart P; Bretaudeau B; Palangie T; Jouve M; Garcia-Giralt E; Asselain B
Bull Cancer; 1982; 69(5):434-42. PubMed ID: 6891903
[TBL] [Abstract][Full Text] [Related]
16. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
[No Abstract] [Full Text] [Related]
17. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
19. Histologic grade in advanced ovarian cancer.
Ozols RF; Garvin AJ; Costa J; Simon RM; Young RC
Cancer Treat Rep; 1979 Feb; 63(2):255-63. PubMed ID: 109199
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Young RC; Chabner BA; Hubbard SP; Canellos GP; DeVita VT
Natl Cancer Inst Monogr; 1975 Oct; 42():145-8. PubMed ID: 825777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]